C 08001

Drug Profile

C 08001

Alternative Names: C08001; Carvedilol CR INNOPHARMAX; Inno-C08001

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator INNOPHARMAX
  • Class Antihypertensives; Carbazoles; Ethanolamines; Heart failure therapies; Ischaemic heart disorder therapies; Phenyl ethers; Propanolamines; Small molecules
  • Mechanism of Action Alpha 1 adrenergic receptor antagonists; Alpha beta adrenergic receptor antagonists; Beta-adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Myocardial infarction
  • No development reported Cardiovascular disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cardiovascular-disorders in Taiwan (PO, Tablet)
  • 15 Mar 2016 Biomarkers information updated
  • 14 Oct 2015 Phase-III clinical trials in Myocardial infarction in Taiwan (PO) before October 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top